Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

mAbs

Volumn 8, Issue 7, 2016, Pages 1195-1209

  Malm, Magdalena ^a   Frejd, Fredrik Y ^b,c   Ståhl, Stefan ^a   Löfblom, John ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; alternative scaffolds; bispecific antibodies; ErbB3; HER3; monoclonal antibodies; protein therapeutics; tumor targeting

Indexed keywords

BISPECIFIC ANTIBODY; ELGEMTUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PATRITUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; SERIBANTUMAB; TRANSFORMING GROWTH FACTOR ALPHA; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LIGAND BINDING; NEOPLASM; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEPHOSPHORYLATION; PROTEIN ENGINEERING; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE SCAFFOLD; ANIMAL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; RECEPTOR, ERBB-3;

EID: 84989339198     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1212147     Document Type: Review

References (147)

1. A.M.Scott, J.D.Wolchok, L.J.Old. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
2. Y.Yarden, M.X.Sliwkowski. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
3. C.A.Zahnow. ErbB receptors and their ligands in the breast. Expert Rev Mol Med 2006; 8:1-21; PMID:16984691; http://dx.doi.org/10.1017/S146239940600010X
4. J.Baselga, S.M.Swain. Novel anticancer targets:revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656
5. Y.Yarden, G.Pines. The ERBB network:at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12:553-63; PMID:22785351; http://dx.doi.org/10.1038/nrc3309
6. H.-S.Cho, D.J.Leahy. Structure of the extracellular region of HER3 reveals an interdomain tether. Science (80-) 2002; 297:1330-3; PMID:12154198; http://dx.doi.org/10.1126/science.1074611
7. H.Ogiso, R.Ishitani, O.Nureki, S.Fukai, M.Yamanaka, J.-H.Kim, K.Saito, A.Sakamoto, M.Inoue, M.Shirouzu, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-87; PMID:12297050; http://dx.doi.org/10.1016/S0092-8674(02)00963-7
8. K.M.Ferguson, M.B.Berger, J.M.Mendrola, H.S.Cho, D.J.Leahy, M.A.Lemmon. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11:507-17; PMID:12620237; http://dx.doi.org/10.1016/S1097-2765(03)00047-9
9. X.Zhang, J.Gureasko, K.Shen, P.A.Cole, J.Kuriyan. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125:1137-49; PMID:16777603; http://dx.doi.org/10.1016/j.cell.2006.05.013
10. N.Jura, Y.Shan, X.Cao, D.E.Shaw, J.Kuriyan. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proceeding Natl Acad Sci United States Am 2009; 106:21608-13; PMID:20007378; http://dx.doi.org/10.1073/pnas.0912101106
11. E.Tzahar, H.Waterman, X.Chen, G.Levkowitz, D.Karunagaran, S.Lavi, B.J.Ratzkin, Y.Yarden. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16:5276-87; PMID:8816440; http://dx.doi.org/10.1128/MCB.16.10.5276
12. R.Pinkas-Kramarski, L.Soussan, H.Waterman, G.Levkowitz, I.Alroy, L.Klapper, S.Lavi, R.Seger, B.J.Ratzkin, M.Sela, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15:2452-67; PMID:8665853
13. D.Graus-Porta, R.R.Beerli, J.M.Daly, N.E.Hynes. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-55; PMID:9130710; http://dx.doi.org/10.1093/emboj/16.7.1647
14. L.N.Klapper, S.Glathe, N.Vaisman, N.E.Hynes, G.C.Andrews, M.Sela, Y.Yarden. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceeding Natl Acad Sci United States Am 1999; 96:4995-5000; PMID:10220407; http://dx.doi.org/10.1073/pnas.96.9.4995
15. T.P.J.Garrett, N.M.McKern, M.Lou, T.C.Elleman, T.E.Adams, G.O.Lovrecz, M.Kofler, R.N.Jorissen, E.C.Nice, A.W.Burgess, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11:495-505; PMID:12620236; http://dx.doi.org/10.1016/S1097-2765(03)00048-0
16. P.M.Guy, J.V.Platko, L.C.Cantley, R.A.Cerione, K.L.Carraway. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proceeding Natl Acad Sci United States Am 1994; 91:8132-6; PMID:8058768; http://dx.doi.org/10.1073/pnas.91.17.8132
17. S.L.Sierke, K.Cheng, H.H.Kim, J.G.Koland. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 1997; 322 (Pt 3:757-63; PMID:9148746); http://dx.doi.org/10.1042/bj3220757
18. F.Shi, S.E.Telesco, Y.Liu, R.Radhakrishnan, M.A.Lemmon. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proceeding Natl Acad Sci United States Am 2010; 107:7692-7; PMID:20351256; http://dx.doi.org/10.1073/pnas.1002753107
19. M.B.Berger, J.M.Mendrola, M.A.Lemmon. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569:332-6; PMID:15225657; http://dx.doi.org/10.1016/j.febslet.2004.06.014
20. N.E.Hynes, G.MacDonald. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21:177-84; PMID:19208461; http://dx.doi.org/10.1016/j.ceb.2008.12.010
21. L.Amiri-Kordestani, G.M.Blumenthal, Q.C.Xu, L.Zhang, S.W.Tang, L.Ha, W.C.Weinberg, B.Chi, R.Candau-Chacon, P.Hughes, et al. FDA approval:ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 2014; 20:4436-41; PMID:24879797; http://dx.doi.org/10.1158/1078-0432.CCR-14-0012
22. D.N.Amin, M.R.Campbell, M.M.Moasser. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010; 21:944-50; PMID:20816829; http://dx.doi.org/10.1016/j.semcdb.2010.08.007
23. D.K.Patel. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28:31S-41S; PMID:18980550; http://dx.doi.org/10.1592/phco.28.11-supp.31S
24. G.Vlacich, R.J.Coffey. Resistance to EGFR-targeted therapy:a family affair. Cancer Cell 2011; 20:423-5; PMID:22014569; http://dx.doi.org/10.1016/j.ccr.2011.10.006
25. M.Sundvall, K.Iljin, S.Kilpinen, H.Sara, O.-P.Kallioniemi, K.Elenius. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:259-68; PMID:18454307; http://dx.doi.org/10.1007/s10911-008-9079-3
26. T.Holbro, R.R.Beerli, F.Maurer, M.Koziczak, C.F.Barbas, N.E.Hynes. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit:ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceeding Natl Acad Sci United States Am 2003; 100:8933-8; PMID:12853564; http://dx.doi.org/10.1073/pnas.1537685100
27. M.H.Kraus, W.Issing, T.Miki, N.C.Popescu, S.A.Aaronson. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family:evidence for overexpression in a subset of human mammary tumors. Proceeding Natl Acad Sci United States Am 1989; 86:9193-7; PMID:2687875; http://dx.doi.org/10.1073/pnas.86.23.9193
28. A.Travis, S.E.Pinder, J.F.Robertson, J.A.Bell, P.Wencyk, W.J.Gullick, R.I.Nicholson, D.N.Poller, R.W.Blamey, C.W.Elston, et al. C-erbB-3 in human breast carcinoma:expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996; 74:229-33; PMID:8688326; http://dx.doi.org/10.1038/bjc.1996.342
29. L.G.Bobrow, R.R.Millis, L.C.Happerfield, W.J.Gullick. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur J Cancer 1997; 33:1846-50; PMID:9470844; http://dx.doi.org/10.1016/S0959-8049(97)00244-X
30. T.Rajkumar, G.W.Stamp, C.M.Hughes, W.J.Gullick. c-erbB3 protein expression in ovarian cancer. Clin Mol Pathol 1996; 49:M199-202; PMID:16696074; http://dx.doi.org/10.1136/mp.49.4.M199
31. E.S.Yi, D.Harclerode, M.Gondo, M.Stephenson, R.W.Brown, M.Younes, P.T.Cagle. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 1997; 10:142-8; PMID:9127320
32. F.Ciardiello, N.Kim, T.Saeki, R.Dono, M.G.Persico, G.D.Plowman, J.Garrigues, S.Radke, G.J.Todaro, D.S.Salomon. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proceeding Natl Acad Sci United States Am 1991; 88:7792-6; PMID:1715580; http://dx.doi.org/10.1073/pnas.88.17.7792
33. M.Reschke, D.Mihic-Probst, E.H.van der Horst, P.Knyazev, P.J.Wild, M.Hutterer, S.Meyer, R.Dummer, H.Moch, A.Ullrich. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008; 14:5188-97; PMID:18698037; http://dx.doi.org/10.1158/1078-0432.CCR-08-0186
34. H.Y.Leung, J.Weston, W.J.Gullick, G.Williams. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. Br J Urol 1997; 79:212-6; PMID:9052472; http://dx.doi.org/10.1046/j.1464-410X.1997.30412.x
35. I.Bièche, P.Onody, S.Tozlu, K.Driouch, M.Vidaud, R.Lidereau. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106:758-65; PMID:12866037; http://dx.doi.org/10.1002/ijc.11273
36. B.Tanner, D.Hasenclever, K.Stern, W.Schormann, M.Bezler, M.Hermes, M.Brulport, A.Bauer, I.B.Schiffer, S.Gebhard, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24:4317-23; PMID:16896008; http://dx.doi.org/10.1200/JCO.2005.04.8397
37. A.Beji, D.Horst, J.Engel, T.Kirchner, A.Ullrich. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012; 18:956-68; PMID:22142822; http://dx.doi.org/10.1158/1078-0432.CCR-11-1186
38. S.P.Soltoff, K.L.Carraway, S.A.Prigent, W.G.Gullick, L.C.Cantley. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14:3550-8; PMID:7515147; http://dx.doi.org/10.1128/MCB.14.6.3550
39. S.A.Prigent, W.J.Gullick. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13:2831-41; PMID:8026468
40. P.Fedi, J.H.Pierce, P.P.di Fiore, M.H.Kraus. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994; 14:492-500; PMID:8264617; http://dx.doi.org/10.1128/MCB.14.1.492
41. T.L.Yuan, L.C.Cantley. PI3K pathway alterations in cancer:variations on a theme. Oncogene 2008; 27:5497-510; PMID:18794884; http://dx.doi.org/10.1038/onc.2008.245
42. R.Naidu, M.Yadav, S.Nair, M.K.Kutty. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998; 78:1385-90; PMID:9823984; http://dx.doi.org/10.1038/bjc.1998.689
43. S.T.Lee-Hoeflich, L.Crocker, E.Yao, T.Pham, X.Munroe, K.P.Hoeflich, M.X.Sliwkowski, H.M.Stern. A central role for HER3 in HER2-amplified breast cancer:implications for targeted therapy. Cancer Res 2008; 68:5878-87; PMID:18632642; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380
44. X.Zhou, M.Tan, V.Stone Hawthorne, K.S.Klos, K.-H.Lan, Y.Yang, W.Yang, T.L.Smith, D.Shi, D.Yu. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004; 10:6779-88; PMID:15501954; http://dx.doi.org/10.1158/1078-0432.CCR-04-0112
45. E.Tokunaga, Y.Kimura, E.Oki, N.Ueda, M.Futatsugi, K.Mashino, M.Yamamoto, M.Ikebe, Y.Kakeji, H.Baba, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006; 118:284-9; PMID:16049961; http://dx.doi.org/10.1002/ijc.21358
46. J.T.Garrett, M.G.Olivares, C.Rinehart, N.D.Granja-Ingram, V.Sánchez, A.Chakrabarty, B.Dave, R.S.Cook, W.Pao, E.McKinely, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108:5021-6; PMID:21385943; http://dx.doi.org/10.1073/pnas.1016140108
47. B.Schoeberl, E.A.Pace, J.B.Fitzgerald, B.D.Harms, L.Xu, L.Nie, B.Linggi, A.Kalra, V.Paragas, R.Bukhalid, et al. Therapeutically targeting ErbB3:a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2:ra31; PMID:19567914; http://dx.doi.org/10.1126/scisignal.2000352
48. E.G.Jeong, Y.H.Soung, J.W.Lee, S.H.Lee, S.W.Nam, J.Y.Lee, N.J.Yoo, S.H.Lee. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 2006; 119:2986-7; PMID:16998794; http://dx.doi.org/10.1002/ijc.22257
49. N.V.Sergina, M.Rausch, D.Wang, J.Blair, B.Hann, K.M.Shokat, M.M.Moasser. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445:437-41; PMID:17206155; http://dx.doi.org/10.1038/nature05474
50. S.Chandarlapaty, A.Sawai, M.Scaltriti, V.Rodrik-Outmezguine, O.Grbovic-Huezo, V.Serra, P.K.Majumder, J.Baselga, N.Rosen. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19:58-71; PMID:21215704; http://dx.doi.org/10.1016/j.ccr.2010.10.031
51. M.Gijsen, P.King, T.Perera, P.J.Parker, A.L.Harris, B.Larijani, A.Kong. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010; 8:e1000563; PMID:21203579; http://dx.doi.org/10.1371/journal.pbio.1000563
52. B.S.Jaiswal, N.M.Kljavin, E.W.Stawiski, E.Chan, C.Parikh, S.Durinck, S.Chaudhuri, K.Pujara, J.Guillory, K.A.Edgar, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013; 23:603-17; PMID:23680147; http://dx.doi.org/10.1016/j.ccr.2013.04.012
53. M.X.Sliwkowski, G.Schaefer, R.W.Akita, J.A.Lofgren, V.D.Fitzpatrick, A.Nuijens, B.M.Fendly, R.A.Cerione, R.L.Vandlen, K.L.Carraway. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269:14661-5; PMID:7514177
54. Q.Sheng, X.Liu, E.Fleming, K.Yuan, H.Piao, J.Chen, Z.Moustafa, R.K.Thomas, H.Greulich, A.Schinzel, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010; 17:298-310; PMID:20227043; http://dx.doi.org/10.1016/j.ccr.2009.12.047
55. T.T.Junttila, R.W.Akita, K.Parsons, C.Fields, G.D.Lewis Phillips, L.S.Friedman, D.Sampath, M.X.Sliwkowski. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40; PMID:19411071; http://dx.doi.org/10.1016/j.ccr.2009.03.020
56. F.M.Yakes, W.Chinratanalab, C.A.Ritter, W.King, S.Seelig, C.L.Arteaga. Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Res 2002; 62:4132-41; PMID:12124352
57. C.A.Ritter, M.Perez-Torres, C.Rinehart, M.Guix, T.Dugger, J.A.Engelman, C.L.Arteaga. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909-19; PMID:17699871; http://dx.doi.org/10.1158/1078-0432.CCR-07-0701
58. K.Yonesaka, K.Zejnullahu, I.Okamoto, T.Satoh, F.Cappuzzo, J.Souglakos, D.Ercan, A.Rogers, M.Roncalli, M.Takeda, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3:99ra86; PMID:21900593; http://dx.doi.org/10.1126/scitranslmed.3002442
59. M.Bezler, J.G.Hengstler, A.Ullrich. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 2012; 6:516-29; PMID:22841590; http://dx.doi.org/10.1016/j.molonc.2012.07.001
60. S.Wang, X.Huang, C.-K.Lee, B.Liu. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010; 29:4225-36; PMID:20498641; http://dx.doi.org/10.1038/onc.2010.180
61. B.Liu, D.Ordonez-Ercan, Z.Fan, S.M.Edgerton, X.Yang, A.D.Thor. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007; 120:1874-82; PMID:17266042; http://dx.doi.org/10.1002/ijc.22423
62. C.Desbois-Mouthon, A.Baron, M.-J.Blivet-Van Eggelpoël, L.Fartoux, C.Venot, F.Bladt, C.Housset, O.Rosmorduc. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway:rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor. Clin Cancer Res 2009; 15:5445-56; PMID:19706799; http://dx.doi.org/10.1158/1078-0432.CCR-08-2980
63. M.K.Jathal, L.Chen, M.Mudryj, P.M.Ghosh. Targeting ErbB3:the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem 2011; 11:131-49; PMID:21603064; http://dx.doi.org/10.2174/187152211795495643
64. S.O.Arnett, J.-L.Teillaud, T.Wurch, J.M.Reichert, C.Dunlop, M.Huber. IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. MAbs December 5–9, 2010; 3:133-52. San Diego, CA USA; PMID:21304271; http://dx.doi.org/10.4161/mabs.3.2.14939
65. T.Sharp, C.Glaus, N.Fettig, A.Hewig, S.Ogbagabriel, D.Freeman, D.Beaupre, D.-R.Hwang, M.J.Welch. Presentation number T206:Pharmacological evaluation of 64Cu - DOTA - AMG 888 (U3-1287) in control and tumor bearing mice using biodistribution and microPET imaging [Internet]. World Mol. Imaging Congr. Large Mol. Imaging Probes Control. Deliv 2011; Available from:http://www.wmicmeeting.org/2011/2011abstracts/data/papers/T206.html
66. P.LoRusso, P.A.Jänne, M.Oliveira, N.Rizvi, L.Malburg, V.Keedy, L.Yee, C.Copigneaux, T.Hettmann, C.-Y.Wu, et al. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013; 19:3078-87; PMID:23591447; http://dx.doi.org/10.1158/1078-0432.CCR-12-3051
67. D.Freeman, S.Ogbagabriel, J.Bready, J.-R.Sun, R.Radinsky, T.Hettmann. Abstract A182:U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN). In:Proceedings of the AACR-NCI-EORTC International Conference:Molecular Targets and Cancer Therapeutics; 2011; http://dx.doi.org/10.1158/1535-7163.targ-11-a182
68. T.Hettmann, M.Schneider, S.Ogbagabriel, J.Xie, G.Juan, S.Hartmann, R.Radinsky, D.J.Freeman. Abstract LB-306:U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation [Internet]. Proc. 101st Annu. Meet. Am. Assoc. Cancer Res. 2010; Available from:http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/8_MeetingAbstracts/LB-306; http://dx.doi.org/10.1158/1538-7445.am10-lb-306
69. C.Li, T.M.Brand, M.Iida, S.Huang, E.A.Armstrong, A.van der Kogel, D.L.Wheeler. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013; 16:79-92; PMID:23998444
70. B.Schoeberl, A.C.Faber, D.Li, M.-C.Liang, K.Crosby, M.Onsum, O.Burenkova, E.Pace, Z.Walton, L.Nie, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485-94; PMID:20215504; http://dx.doi.org/10.1158/0008-5472.CAN-09-3145
71. Merrimack Pharmaceuticals Announces Results From A Phase two Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers [Internet]. [cited 2016Apr7]; Available from:http://investors.merrimack.com/releasedetail.cfm?releaseid=801512
72. Merrimack Pharmaceuticals' MM-121 Demonstrates Positive Signal in Two Phase two ER/PR+ Breast Cancer Studies [Internet]. [cited 2016Apr7]; Available from:http://investors.merrimack.com/releasedetail.cfm?releaseid=809634
73. G.MacBeath, B.Adiwijaya, J.Liu, L.Sequist, E.Pujade-Lauraine, M.Higgins, I.Tabah-Fisch, J.Pearlberg, V.Moyo, W.Kubasek, et al. A meta-analysis of biomarkers in three randomized, phase two studies of MM-121, a ligand-blocking anti-ErbB3 antibody, in patients with ovarian, lung, and breast cancers. In:European Society for Medical Oncology (ESMO) Annual meeting, Madrid, Spain, 2014.
74. A.P.Garner, C.U.Bialucha, E.R.Sprague, J.T.Garrett, Q.Sheng, S.Li, O.Sineshchekova, P.Saxena, C.R.Sutton, D.Chen, et al. An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin. Cancer Res 2013; 73:6024-35; PMID:23928993; http://dx.doi.org/10.1158/0008-5472.CAN-13-1198
75. C.Mirschberger, C.B.Schiller, M.Schräml, N.Dimoudis, T.Friess, C.A.Gerdes, U.Reiff, V.Lifke, G.Hoelzlwimmer, I.Kolm, et al. RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation. Cancer Res 2013; 73:5183-94; PMID:23780344; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099
76. D.Meulendijks, M.P.J.K.Lolkema, E.E.Voest, M.J.De Jonge, S.Sleijfer, J.H.Schellens, T.Fleitas, A.Cervantes-Ruiperez, M.Martinez-Garcia, A.Taus, et al. Abstract 2522:A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. | 2013 ASCO Annual Meeting | Abstracts | Meeting Library [Internet]. 2013 ASCO Annu. Meet. 2013 [cited 2014Feb26]; Available from:http://meetinglibrary.asco.org/content/110542-132
77. D.Meulendijks, W.Jacob, M.Martinez-Garcia, A.Taus, M.Lolkema, E.Voest, M.H.Langenberg, T.Fleitas, A.Cervantes, M.J.A.de Jonge, et al. First-in-human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-positive Solid Tumors. Clin Cancer Res 2016; 22(4):877-85; PMID:26463709; http://dx.doi.org/10.1158/1078-0432.ccr-15-1683
78. K.Meetze, S.Tyler, K.Clark, E.Mazsa, A.Delpero, J.Gyuris, S.Vincent. 414 The Anti-tumor Activity of the ERBB3 Inhibitory Antibody AV-203 in Patient Derived Tumor Explant Models. Eur J Cancer 2012; 48:126; http://dx.doi.org/10.1016/S0959-8049(12)72212-8
79. S.Lee, E.B.Greenlee, J.R.Amick, G.F.Ligon, J.S.Lillquist, E.J.Natoli, Y.Hadari, D.Alvarado, J.Schlessinger. Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration. Proc Natl Acad Sci U S A 2015; 112:13225-30; PMID:26460020; http://dx.doi.org/10.1073/pnas.1518361112
80. Z.Xiao, R.A.Carrasco, K.Schifferli, K.Kinneer, R.Tammali, H.Chen, R.Rothstein, L.Wetzel, C.Yang, P.Chowdhury, et al. A potent HER3 monoclonal antibody that blocks both ligand-dependent and -independent activities:differential impacts of PTEN status on tumor response. Mol Cancer Ther 2016; 1535–7163.MCT – 15–0555 15(2):689-701; http://dx.doi.org/10.1158/1535-7163.mct-15-0555
81. Y.Nagata, K.-H.Lan, X.Zhou, M.Tan, F.J.Esteva, A.A.Sahin, K.S.Klos, P.Li, B.P.Monia, N.T.Nguyen, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6:117-27; PMID:15324695; http://dx.doi.org/10.1016/j.ccr.2004.06.022
82. L.Aurisicchio, E.Marra, L.Luberto, F.Carlomosti, C.De Vitis, A.Noto, Z.Gunes, G.Roscilli, G.Mesiti, R.Mancini, et al. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. J Cell Physiol 2012; 227:3381-8; PMID:22213458; http://dx.doi.org/10.1002/jcp.24037
83. L.Aurisicchio, E.Marra, G.Roscilli, R.Mancini, G.Ciliberto. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 2012; 3:744-58; PMID:22889873; http://dx.doi.org/10.18632/oncotarget.550
84. F.Belleudi, E.Marra, F.Mazzetta, L.Fattore, M.R.Giovagnoli, R.Mancini, L.Aurisicchio, M.R.Torrisi, G.Ciliberto. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle 2012; 11:1455-67; PMID:22421160; http://dx.doi.org/10.4161/cc.19861
85. G.Sala, S.Traini, M.D'Egidio, G.Vianale, C.Rossi, E.Piccolo, R.Lattanzio, M.Piantelli, N.Tinari, P.G.Natali, et al. An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene 2012; 31:1275-86; PMID:21822299; http://dx.doi.org/10.1038/onc.2011.322
86. G.Sala, I.G.Rapposelli, R.Ghasemi, E.Piccolo, S.Traini, E.Capone, C.Rossi, A.Pelliccia, A.Di Risio, M.D'Egidio, et al. EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Transl Oncol 2013; 6:676-84; PMID:24466370; http://dx.doi.org/10.1593/tlo.13475
87. Y.Lazrek, O.Dubreuil, V.Garambois, N.Gaborit, C.Larbouret, C.Le Clorennec, G.Thomas, W.Leconet, M.Jarlier, M.Pugnière, et al. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 2013; 15:335-47; PMID:23479511; http://dx.doi.org/10.1593/neo.121960
88. P.K.Foreman, M.Gore, P.A.Kobel, L.Xu, H.Yee, C.Hannum, H.Ho, S.M.Wang, H.V.Tran, M.Horowitz, et al. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11:1411-20; PMID:22553357; http://dx.doi.org/10.1158/1535-7163.MCT-12-0068
89. J.M.Reichert. Antibodies to watch in 2016. MAbs 8:197-204; PMID:26651519; http://dx.doi.org/10.1080/19420862.2015.1125583
90. Plückthun A. Alternative Scaffolds:Expanding the Options of Antibodies. In:Little M, editor. Recombinant Antibodies for Immunotherapy. Cam- 1280 bridge:Cambridge University Press; 2009. 243-272; http://dx.doi.org/10.1017/CBO9780511596773.021
91. F.Y.Frejd. Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy. In:T.Stigbrand, J.Carlsson, G.P.Adams, editors. Targeted Radionuclide Tumor Therapy. Dordrecht:Springer Netherlands; 2008. 89-116; http://dx.doi.org/10.1007/978-1-4020-8696-0_6
92. R.A.Beckman, L.M.Weiner, H.M.Davis. Antibody constructs in cancer therapy:protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109:170-9; PMID:17154393; http://dx.doi.org/10.1002/cncr.22402
93. Dimitrov DS. Therapeutic proteins. In:Voynov V, Caravella JA, editors. Methods in Molecular Biology. Humana Press; 2012. 1-26; http://dx.doi.org/10.1007/978-1-61779-921-1_1
94. A.Beck, T.Wurch, C.Bailly, N.Corvaia. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
95. A.L.Nelson. Antibody fragments:hope and hype. MAbs 2010; 2:77-83; PMID:20093855; http://dx.doi.org/10.4161/mabs.2.1.10786
96. P.Holliger, P.J.Hudson. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142
97. Ablynx patent anti-Her3 [Internet]. [cited 2016May9]; Available from:http://tabs.craic.com/antibodies/1680
98. S.Muyldermans. Nanobodies:Natural Single-Domain Antibodies. Annu Rev Biochem 2013; 82:775-97; PMID:23495938; http://dx.doi.org/10.1146/annurev-biochem-063011-092449
99. U.D.Staerz, O.Kanagawa, M.J.Bevan. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314:628-31; PMID:2859527; http://dx.doi.org/10.1038/314628a0
100. D.Müller, R.E.Kontermann. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9:319-26; PMID:17694444
101. D.Przepiorka, C.-W.Ko, A.Deisseroth, C.L.Yancey, R.Candau-Chacon, H.-J.Chiu, B.J.Gehrke, C.Gomez-Broughton, R.C.Kane, S.Kirshner, et al. FDA Approval:Blinatumomab. Clin Cancer Res 2015; 21:4035-9; PMID:26374073; http://dx.doi.org/10.1158/1078-0432.CCR-15-0612
102. D.Holmes. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
103. R.Kontermann. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
104. D.M.Goldenberg, R.M.Sharkey, G.Paganelli, J.Barbet, J.-F.Chatal. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24:823-34; PMID:16380412; http://dx.doi.org/10.1200/JCO.2005.03.8471
105. C.Klein, C.Sustmann, M.Thomas, K.Stubenrauch, R.Croasdale, J.Schanzer, U.Brinkmann, H.Kettenberger, J.T.Regula, W.Schaefer. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
106. J.B.Ridgway, L.G.Presta, P.Carter. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
107. W.Schaefer, J.T.Regula, M.Bähner, J.Schanzer, R.Croasdale, H.Dürr, C.Gassner, G.Georges, H.Kettenberger, S.Imhof-Jung, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proceeding Natl Acad Sci United States Am 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
108. Klein C, Schaefer W Regula J. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs 2016; 8:1010-1020
109. M.Friedman, S.Lindström, L.Ekerljung, H.Andersson-Svahn, J.Carlsson, H.Brismar, L.Gedda, F.Y.Frejd, S.Ståhl. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem 2009; 54:121-31; PMID:19492986; http://dx.doi.org/10.1042/BA20090096
110. A.Eggel, M.J.Baumann, P.Amstutz, B.M.Stadler, M.Vogel. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol 2009; 393:598-607; PMID:19683003; http://dx.doi.org/10.1016/j.jmb.2009.08.014
111. Y.L.Boersma, G.Chao, D.Steiner, K.D.Wittrup, A.Plückthun. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 2011; 286:41273-85; PMID:21979953; http://dx.doi.org/10.1074/jbc.M111.293266
112. C.Jost, J.Schilling, R.Tamaskovic, M.Schwill, A.Honegger, A.Plückthun. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 2013; 21:1979-91; PMID:24095059; http://dx.doi.org/10.1016/j.str.2013.08.020
113. S.L.Emanuel, L.J.Engle, G.Chao, R.-R.Zhu, C.Cao, Z.Lin, A.P.Yamniuk, J.Hosbach, J.Brown, E.Fitzpatrick, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48; PMID:21099371; http://dx.doi.org/10.4161/mabs.3.1.14168
114. R.Smith, A.Duguay, A.Bakker, P.Li, J.Weiszmann, M.R.Thomas, B.M.Alba, X.Wu, J.Gupte, L.Yang, et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein. PLoS One 2013; 8:e61432; PMID:23630589; http://dx.doi.org/10.1371/journal.pone.0061432
115. G.Schaefer, L.Haber, L.M.Crocker, S.Shia, L.Shao, D.Dowbenko, K.Totpal, A.Wong, C.V.Lee, S.Stawicki, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
116. S.Huang, C.Li, E.A.Armstrong, C.R.Peet, J.Saker, L.C.Amler, M.X.Sliwkowski, P.M.Harari. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
117. C.F.McDonagh, A.Huhalov, B.D.Harms, S.Adams, V.Paragas, S.Oyama, B.Zhang, L.Luus, R.Overland, S.Nguyen, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
118. J.B.Fitzgerald, B.W.Johnson, J.Baum, S.Adams, S.Iadevaia, J.Tang, V.Rimkunas, L.Xu, N.Kohli, R.Rennard, et al. MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors. Mol Cancer Ther 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
119. M.K.Robinson, K.M.Hodge, E.Horak, A.L.Sundberg, M.Russeva, C.C.Shaller, M.von Mehren, I.Shchaveleva, H.H.Simmons, J.D.Marks, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx.doi.org/10.1038/sj.bjc.6604700
120. Tissue expression of ERBB3 - Summary - The Human Protein Atlas [Internet]. [cited 2016Apr12]; Available from:http://www.proteinatlas.org/ENSG00000065361-ERBB3/tissue
121. D.Cervantes-Ruiperez Andres Juric, M.Hidalgo, W.A.Messersmith, G.R.Blumenschein, J.Baselga, D.R.Perez, R.Dienstmann, A.Calles, A.Jimeno, S.Sanabria, et al. Abstract 2568:A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors:Expansion cohorts. | 2012 ASCO Annual Meeting | Abstracts | Meeting Library [Internet]. 2012 ASCO Annu. Meet. 2012 [cited 2014Feb28]; Available from:http://meetinglibrary.asco.org/content/95245-114
122. N.Viola-Villegas, S.Carlin, K.Sevak, J.S.Lewis. Imaging pancreatic cancer with a 89Zr-radiolabeled EGFR/HER3 dual-action antibody. In:World Molecular Imaging Society. 2013.
123. A.J.Porter, G.Beschen, T.W.Durso, J.M.Ercolino, M.Othersen Gorman, J.Horne, G.Lester, D.Quattrone. Experimental breast cancer drug owes origins to fox chase lab. Fox Chase Cancer Center Forward 2009; 29
124. Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results [Internet]. [cited 2016Apr14]; Available from:http://investors.merrimack.com/releasedetail.cfm?releaseid=898519
125. L.Xu, N.Kohli, R.Rennard, Y.Jiao, M.Razlog, K.Zhang, J.Baum, B.Johnson, J.Tang, B.Schoeberl, et al. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 5:237-54; PMID:23392215; http://dx.doi.org/10.4161/mabs.23363
126. J.C.Kang, J.S.Poovassery, P.Bansal, S.You, I.M.Manjarres, R.J.Ober, E.S.Ward. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs 2014; 6:340-53; PMID:24492289; http://dx.doi.org/10.4161/mabs.27658
127. J.S.Poovassery, J.C.Kang, D.Kim, R.J.Ober, E.S.Ward. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer 2015; 137:267-77; PMID:25471734; http://dx.doi.org/10.1002/ijc.29378
128. J.Gu, J.Yang, Q.Chang, Z.Liu, T.Ghayur, J.Gu. Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities. PLoS One 2015; 10:e0124135; PMID:25997020; http://dx.doi.org/10.1371/journal.pone.0124135
129. S.Hu, W.Fu, W.Xu, Y.Yang, M.Cruz, S.D.Berezov, D.Jorissen, H.Takeda, W.Zhu. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2015; 75:159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
130. J.Bostrom, S.-F.Yu, D.Kan, B.A.Appleton, C.V.Lee, K.Billeci, W.Man, F.Peale, S.Ross, C.Wiesmann, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
131. J.Löfblom, F.Y.Frejd, S.Ståhl. Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 2011; 22:843-8; PMID:21726995; http://dx.doi.org/10.1016/j.copbio.2011.06.002
132. R.Vazquez-Lombardi, T.G.Phan, C.Zimmermann, D.Lowe, L.Jermutus, D.Christ. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov Today 2015; 20:1271-83; PMID:26360055; http://dx.doi.org/10.1016/j.drudis.2015.09.004
133. T.Wurch, A.Pierré, S.Depil. Novel protein scaffolds as emerging therapeutic proteins:from discovery to clinical proof-of-concept. Trends Biotechnol 2012; 30:575-82; PMID:22944617; http://dx.doi.org/10.1016/j.tibtech.2012.07.006
134. W.R.Strohl. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs 2015; 29:215-39; PMID:26177629; http://dx.doi.org/10.1007/s40259-015-0133-6
135. F.Y.Frejd. Half-Life Extension by Binding to Albumin through an Albumin Binding Domain. In:Therapeutic Proteins. Weinheim, Germany:Wiley-VCH Verlag GmbH & Co. KGaA; 2012. page 269-83; http://dx.doi.org/10.1002/9783527644827.ch14
136. M.Uhlen, B.Guss, B.Nilsson, S.Gatenbeck, L.Philipson, M.Lindberg. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem 1984; 259:1695-702; PMID:6319407
137. N.Kronqvist, M.Malm, L.Göstring, E.Gunneriusson, M.Nilsson, I.Höidén Guthenberg, L.Gedda, F.Y.Frejd, S.Ståhl, J.Löfblom. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 2011; 24:385-96; PMID:21177282; http://dx.doi.org/10.1093/protein/gzq118
138. L.Göstring, M.Malm, I.Höidén-Guthenberg, F.Y.Frejd, S.Ståhl, J.Löfblom, L.Gedda. Cellular effects of HER3-specific affibody molecules. PLoS One 2012; 7:e40023; PMID:22768204; http://dx.doi.org/10.1371/journal.pone.0040023
139. M.Malm, N.Kronqvist, H.Lindberg, L.Gudmundsdotter, T.Bass, F.Y.Frejd, I.Höidén-Guthenberg, Z.Varasteh, A.Orlova, V.Tolmachev, et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 2013; 8:e62791; PMID:23675426; http://dx.doi.org/10.1371/journal.pone.0062791
140. A.Orlova, M.Malm, M.Rosestedt, Z.Varasteh, K.Andersson, R.K.Selvaraju, M.Altai, H.Honarvar, J.Strand, S.Ståhl, et al. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. Eur J Nucl Med Mol Imaging 2014; 41(7):1450-9; PMID:24622956; http://dx.doi.org/10.1007/s00259-014-2733-7
141. K.G.Andersson, M.Rosestedt, Z.Varasteh, M.Malm, M.Sandström, V.Tolmachev, J.Löfblom, S.Ståhl, A.Orlova. Comparative evaluation of 111In-labeled NOTAconjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncol Rep 2015; 34:1042-8; PMID:26059265; http://dx.doi.org/10.3892/or.2015.4046
142. M.Rosestedt, K.G.Andersson, B.Mitran, V.Tolmachev, J.Löfblom, A.Orlova, S.Ståhl. Affibody-mediated PET imaging of HER3 expression in malignant tumours. Sci Rep 2015; 5:15226; PMID:26477646; http://dx.doi.org/10.1038/srep15226
143. D.W.LaFleur, D.Abramyan, P.Kanakaraj, R.G.Smith, R.R.Shah, G.Wang, X.-T.Yao, S.Kankanala, E.Boyd, L.Zaritskaya, et al. Monoclonal antibody therapeutics with up to five specificities:functional enhancement through fusion of target-specific peptides. MAbs 2013; 5:208-18; PMID:23575268; http://dx.doi.org/10.4161/mabs.23043
144. M.Malm, T.Bass, L.Gudmundsdotter, M.Lord, F.Y.Frejd, S.Ståhl, J.Löfblom. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnol J 2014; 9:1215-22; PMID:24678002; http://dx.doi.org/10.1002/biot.201400009
145. E.J.Razumienko, D.A.Scollard, R.M.Reilly. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J Nucl Med 2012; 53:1943-50; PMID:23096164; http://dx.doi.org/10.2967/jnumed.112.106906
146. Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016Apr12]; Available from:https://clinicaltrials.gov/ct2/show/NCT02345174?term=erbb3&rank=3
147. A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016Apr12]; Available from:https://clinicaltrials.gov/ct2/show/NCT01482377?term=her3&rank=5